New! Sign up for our free email newsletter.
Science News
from research organizations

1 in 8 Americans have already tried Ozempic and similar weight loss medications

GLP-1 drugs are reshaping America’s weight loss landscape, but not without side effects.

Date:
September 14, 2025
Source:
RAND Corporation
Summary:
GLP-1 drugs like Ozempic have transformed weight loss in the U.S., with nearly 12% of Americans having tried them, according to a new RAND report. Usage is especially high among women aged 50 to 64, while men catch up in older groups. Despite effectiveness, side effects like nausea and diarrhea are common, and most Americans say they don’t plan to take them.
Share:
FULL STORY

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report.

Surveying a nationally representative sample of 8,793 Americans, researchers found that 11.8% have used GLP-1 agonists and 14% say they are interested in using the drugs. Meanwhile, 74% say they do not plan to take the medications.

Among those who have used GLP-1 drugs, about half report they have experienced nausea and about one-third experienced diarrhea -- the two most-common side effects associated with the medications.

The report is the most-recent and largest survey to date that estimates how many Americans have used the drugs that have revolutionized weight loss care. The report outlines use of GLP-1 drugs by both age and sex.

The use of Ozempic and other GLP-1 medications has increased sharply in recent years since studies demonstrated the drugs can help people significantly aid weight loss. Since 2020, the number of prescriptions for the drugs has more than tripled.

RAND researchers surveyed participants of the RAND American Life Panel to ask about use of GLP-1 drugs and their experiences with side effects. The survey was performed during April and May of 2025.

The results show that women tend to use GLP-1 drugs at higher rates than men, although there is considerable variability within age groups.

Use of GLP-1 drugs is most common among those between the ages of 50 and 64, with the highest rate of use found among women in the age group. Among those 65 and older, use of GLP-1 drugs is somewhat higher for men than for women. Conversely, among those between the ages of 30 and 49, women are more than twice as likely to have used a GLP-1 than their male peers.

The RAND American Life Panel is a probability sample-based survey panel of about 11,000 active, regularly interviewed respondents aged 12 and older. The panel was developed by RAND in 2006.

The report, "New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States," is available at www.rand.org. Authors of the report are Robert Bozick, Shannon Donofry and Katherine M. Rancaño.

The publication is the first in what is planned to be a series of brief reports that highlights topline descriptive findings from surveys run on the RAND American Life Panel.

The RAND Education and Labor division is dedicated to improving education and expanding economic opportunities for all through research and analysis.


Story Source:

Materials provided by RAND Corporation. Note: Content may be edited for style and length.


Journal Reference:

  1. Robert Bozick, Shannon D. Donofry, Katherine M. Rancaño. New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States. RAND, 6 Aug 2025 DOI: 10.7249/RRA4153-1

Cite This Page:

RAND Corporation. "1 in 8 Americans have already tried Ozempic and similar weight loss medications." ScienceDaily. ScienceDaily, 14 September 2025. <www.sciencedaily.com/releases/2025/09/250913232936.htm>.
RAND Corporation. (2025, September 14). 1 in 8 Americans have already tried Ozempic and similar weight loss medications. ScienceDaily. Retrieved September 14, 2025 from www.sciencedaily.com/releases/2025/09/250913232936.htm
RAND Corporation. "1 in 8 Americans have already tried Ozempic and similar weight loss medications." ScienceDaily. www.sciencedaily.com/releases/2025/09/250913232936.htm (accessed September 14, 2025).

Explore More

from ScienceDaily

RELATED STORIES